ALX Oncology says Phase 2 ASPEN-06 study shows 40.3% response rate for evorpacept combo in HER2-positive gastric cancer
Bitget2026/09/28 12:04- ALX Oncology reported already-published Phase 2 ASPEN-06 data in Nature Medicine for evorpacept in previously treated HER2-positive gastric cancer.
- The regimen delivered stronger tumor shrinkage and longer-lasting benefit than standard therapy, with the largest gains in a biomarker-defined subgroup.
- Findings supported CD47 expression as a potential patient-selection marker, reinforcing the company’s biomarker-driven development strategy.
- ALX chose not to pursue a U.S. registrational Phase 3 path in gastric cancer, shifting focus toward potential partnerships for that program.
- Management kept its mid-2027 target for a topline readout from 80 patients in the ongoing Phase 2 ASPEN-09-Breast trial.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The British Pound rallies on a UK growth upgrade and gives more than half back
Only twice in history! S&P 500 equal-weight index is expected to record seven consecutive weeks of decline this week
The S&P 500 Equal Weight Index is expected to fall for a seventh consecutive week. If this downward trend continues through Friday, it will mark only the third time in history that the index has experienced seven straight weeks of decline.
Trump “bites” Powell, demanding his resignation from the Federal Reserve Board, citing severe cost overruns in headquarters renovation.
U.S. President Trump on Wednesday called for former Federal Reserve Chairman Powell to resign from his position as a Fed governor, following an inspector general report on the Federal Reserve headquarters renovation project, which highlighted a series of management issues that led to significant cost overruns.
Crypto prices
More
